The Miami Entrepreneur

Eli Lilly reports positive data in Phase 3 trial of weight-loss drug as treatment for sleep apnea

Read Time:5 Second

Zepbound reduced apnea effect by up to 63% and achieved about 20% weight loss after a year.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post U.K. pushes to create ‘smokefree generation’ by banning sale of cigarettes to anyone born after 2009
Next post Why the bond market still holds the cards as Fed walks back its pivot talk